Zacks: InflaRx N.V. (NASDAQ:LUMO) Receives Consensus Rating of “Strong Buy” from Analysts

InflaRx N.V. (NASDAQ:LUMO) has been assigned an average broker rating score of 1.00 (Strong Buy) from the two analysts that provide coverage for the stock, Zacks Investment Research reports. Two research analysts have rated the stock with a strong buy rating. InflaRx’s rating score has improved by 66.7% in the last three months as a result of a number of analysts’ ratings changes.

Brokerages have set a 12 month consensus target price of $23.00 for the company and are forecasting that the company will post ($0.83) EPS for the current quarter, according to Zacks. Zacks has also assigned InflaRx an industry rank of 16 out of 254 based on the ratings given to related companies.

LUMO has been the topic of a number of analyst reports. Jefferies Financial Group initiated coverage on InflaRx in a research note on Thursday, April 16th. They set a “buy” rating and a $12.00 target price on the stock. Roth Capital started coverage on InflaRx in a research note on Friday, May 1st. They set a “buy” rating on the stock.

Shares of LUMO traded up $0.60 during mid-day trading on Friday, reaching $14.10. 72,496 shares of the company’s stock traded hands, compared to its average volume of 33,677. InflaRx has a 12 month low of $6.74 and a 12 month high of $32.40.

InflaRx (NASDAQ:LUMO) last released its earnings results on Friday, February 28th. The company reported ($1.98) EPS for the quarter, beating analysts’ consensus estimates of ($2.52) by $0.54. The firm had revenue of $0.43 million for the quarter, compared to analysts’ expectations of $0.25 million. InflaRx had a negative return on equity of 41.50% and a negative net margin of 4,592.84%. As a group, equities research analysts predict that InflaRx will post -3.49 earnings per share for the current year.

About InflaRx

Lumos Pharma, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for severe, rare, and genetic diseases. Its lead therapeutic candidate LUM-201 is an oral growth hormone stimulating small molecule, which is in Phase 2 clinical trial for the treatment of pediatric growth hormone deficiency.

Further Reading: Hedge Funds – How They Work For Investors

Get a free copy of the Zacks research report on InflaRx (LUMO)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for InflaRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InflaRx and related companies with's FREE daily email newsletter.